Loading data for QURE — first visit, this takes a few seconds.
uniQure N.V.
44.51 +0.04 (0.09%)
- Рыночная капитализация
- $3.11B
- Объём торгов
- 1.24M
- Следующая дата отчётности
- Nov 9, 2026
uniQure N.V. (QURE): цена акции, анализ и данные
Внутренняя стоимость
Прогноз аналитиков
Прогнозы по акции →Последние результаты
| Отчитано | К прогнозу | Изменение г/г | |
|---|---|---|---|
| Выручка | $5.84M | n/a | +11.00% |
| EPS | -$1,07 | -$0,36 | -78.33% |
Метрики
- Бид
- 32.35
- Рыночная капитализация
- 3.11B
- Выручка (TTM)
- 18.7M
- Чистая прибыль (TTM)
- -252M
- 0.94
- -4.06
- n/a
- -14.7
- P/B (TTM)
- 9.58
- P/S (TTM)
- 166.36
- Дата отчёта
- Nov 9, 2026
- Аск
- 44.5
- Объём торгов
- 1,241,783
- Ср. объём (20д)
- 1,858,733
- Открытие
- 44.94
- Пред. закрытие
- 44.47
- Диапазон дня
- 44.04 - 45.30
- Диапазон за 52 недели
- 8.73 - 71.50
- Аналитики
- n/a
- Целевая цена
- n/a
- Дивиденды
- n/a
- Дата отсечки
- n/a
О компании uniQure N.V.
Профиль →uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in Phase I/II clinical study for the treatment of Huntington's disease. The company also develops AMT-260, which is in Phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in Phase I/IIa clinical trial to treat superoxide dismutase enzyme-amyotrophic lateral sclerosis; and AMT-191, an investigational gene therapy candidate which is in phase I/IIa clinical trial for the treatment of fabry disease. It has a licensing agreement with Apic Bio to develop, manufacture, and commercialize intrathecally administered investigational gene therapy for ALS caused by mutations in SOD-1; and development and commercial supply agreement with CLS Bhering. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in Phase I/II clinical study for the treatment of Huntington's disease. The company also develops AMT-260, which is in Phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in Phase I/IIa clinical trial to treat superoxide dismutase enzyme-amyotrophic lateral sclerosis; and AMT-191, an investigational gene therapy candidate which is in phase I/IIa clinical trial for the treatment of fabry disease. It has a licensing agreement with Apic Bio to develop, manufacture, and commercialize intrathecally administered investigational gene therapy for ALS caused by mutations in SOD-1; and development and commercial supply agreement with CLS Bhering. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
Отрасль Biotechnology
Сектор Healthcare
Дата IPO Feb 5, 2014
Сотрудники 221
Биржа NasdaqGS
Тикер QURE